Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 36
Filtrer
1.
Acta Endocrinol (Buchar) ; 18(4): 508-511, 2022.
Article de Anglais | MEDLINE | ID: mdl-37152885

RÉSUMÉ

Proprotein convertase 1/3 (PC 1/3) deficiency is a rare, autosomal recessive disorder caused by mutations in the PCSK1 gene. The disease is characterized by early-onset chronic diarrhea/malabsorption, followed by severe obesity and hormonal deficiencies such as hypocortisolism, hypothyroidism, diabetes insipidus, hypogonadism, growth deficiency, and diabetes mellitus. Ewing's sarcoma is a rare tumor, usually of small dimensions of neuroectodermal origin that is difficult to distinguish pathologically from a primitive neuroectodermal tumor. A 22-year-old female patient with PC 1/3 deficiency was admitted to our clinic with recurrent urinary tract infections. Magnetic resonance imaging (MRI) revealed an 11x12 cm pelvic mass displacing the uterus. A core-needle biopsy was performed on the pelvic mass. As a result of the pathological evaluation, it was diagnosed with pelvic Ewing's sarcoma. The patient was started on the VAC-IE chemotherapy protocol. We report a case of pelvic Ewing's sarcoma in a patient with PC 1/3 deficiency. Further research is needed to assess malignancy risk in metabolic disorders including very rare disorders like PC 1/3 deficiency.

2.
Biotech Histochem ; 95(1): 27-36, 2020 Jan.
Article de Anglais | MEDLINE | ID: mdl-31264472

RÉSUMÉ

Ovarian cancer has a high mortality rate. Serous carcinoma is the most common subtype and can be detected by distant or lymph node metastasis in advanced stages. Apelin, an adipokine associated with obesity, and its receptor, APJ, participate in lymphatic invasion. Angiogenesis also can affect lymph node involvement in serous ovarian carcinomas. We investigated apelin/APJ receptor immunoreactivity in stages III and IV ovarian cancer with or without lymph node involvement and correlated the results with body mass index (BMI) to determine whether the potential relation of the two affects the outcome of the cancer. We investigated 30 patients diagnosed between 2014 and 2016 with high grade serous ovarian cancer. Tumor:stroma ratio, indirect immunoperoxidase method, H-score and MATLAB analysis were performed. In obese and pre-obese patients, tumor apelin immunoreactivity was stronger than for patients with normal BMI. Tumor:stroma ratio was correlated with survival and lymph node involvement. Strong apelin and moderate APJ immunoreactivity was detected in both lymph node negative and positive patients. BMI was related to both survival outcome and apelin immunoreactivity. BMI, adipokines such as apelin, and the stromal compartment play critical roles in advanced stage serous carcinomas.


Sujet(s)
Apeline/métabolisme , Indice de masse corporelle , Carcinomes/classification , Carcinomes/métabolisme , Tumeurs de l'ovaire/métabolisme , Adulte , Sujet âgé , Apeline/génétique , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Adulte d'âge moyen , Tumeurs de l'ovaire/classification
3.
Med Oral Patol Oral Cir Bucal ; 23(4): e443-e448, 2018 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-29924761

RÉSUMÉ

BACKGROUND: Odontogenic keratocysts have been reported with high recurrence rates in the literature so various treatment modalities from simple enucleation to resection have been performed to achieve the cure. The purpose of this retrospective study was to investigate the recurrence rate of odontogenic keratocysts (OKCs) treated by enucleation and peripheral ostectomy. MATERIAL AND METHODS: An electronic search of the database of the Hacettepe University, Faculty of Medicine, Department of Pathology, was undertaken to identify patients histologically diagnosed with OKCs treated at Department of Oral and Maxillofacial Surgery between 2001 and 2015. RESULTS: In total, 81 patients were studied. The mean age at the time of diagnosis was 42 years, and the male:female ratio was 1:0.7. OKCs were located primarily in the posterior mandibular region (41%). Twenty-seven patients were re-examined to determine the recurrence rate. The mean follow-up period was 5 years (range, 1-12 years). The recurrence rate was 14.8%. The relationship between location of the lesion and recurrence was not statistically significant (p = 0.559). There was also no statistically significant relation between the recurrence rate and treatment option of teeth involved in the lesion (p = 0.579). CONCLUSIONS: The authors conclude that treatment of OKCs by enucleation with peripheral ostectomy is associated with minimal morbidity and is preferred over other aggressive treatment modalities. Meticulous radiographic examination and careful surgical resection may decrease the recurrence rate of OKCs.


Sujet(s)
Kystes odontogènes/chirurgie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Procédures de chirurgie maxillofaciale et buccodentaire/méthodes , Ostéotomie , Récidive , Études rétrospectives , Facteurs temps , Jeune adulte
4.
Pathol Oncol Res ; 22(3): 593-9, 2016 Jul.
Article de Anglais | MEDLINE | ID: mdl-26797858

RÉSUMÉ

Ovarian cancer is the most common cause of gynecologic cancer death. Both morphologically and immunohistochemically, metastatic mucinous tumors are the best mimickers of mucinous ovarian tumors; its pathogenesis still remains a mystery. PAX2 and PAX8 immunohisyochemistries are useful for differentiating numerous primary tumour types from metastatic ones. There are few studies in literature about PAX expressions in mucinous and seromucinous tumors. None of these are takes into account the histologic type (whether it is seromucinous or mucinous) or the metastatic origin. With this purpose hematoxylin and eosine slides of ovarian mucinous and seromucinous tumors were re-evaluated and one block was chosen for each case. The study included 76 ovarian mucinous and seromucinous tumors of the ovary reported in Hacettepe University department of pathology between 2000 and 2013. Tissue microarray (TMA) was designed from the chosen blocks, PAX2, PAX8, CDX2 immunostains was preformed to the TMA slides. As a result, most of the metastatic cases were negative for PAX2 (91.2 %) and PAX8 (86.3 %), many were diffusely and strongly positive for CDX2 (68.2 %). Seromucinous tumors were devoid of CDX2 expression; but all cases (except one) displayed strong and diffuse positivity with PAX8. In other words differing from mucinous tumors, seromucinous tumors show strong PAX8 positivity-similar to serous tumors. This study shows that PAX8 and CDX2 could be useful in differentiating primary mucinous from metastatic tumor. Furthermore unlike the homogeneity in seromucinous tumors for PAX8 and CDX2 mucinous tumors shows heterogeneity with different expression patterns.


Sujet(s)
Adénocarcinome mucineux/génétique , Facteurs de transcription CDX2/génétique , Métastase tumorale/génétique , Tumeurs de l'ovaire/génétique , Facteur de transcription PAX2/génétique , Facteur de transcription PAX-8/génétique , Adénocarcinome mucineux/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques tumoraux/génétique , Femelle , Humains , Immunohistochimie , Adulte d'âge moyen , Métastase tumorale/anatomopathologie , Tumeurs de l'ovaire/anatomopathologie
5.
Pathologica ; 107(3-4): 201-4, 2015.
Article de Anglais | MEDLINE | ID: mdl-26946877

RÉSUMÉ

Epithelioid trophoblastic tumor is a rare non-molar gestational trophoblastic disease. A 40-year-old multiparous woman was incidentally diagnosed with epithelioid trophoblastic tumor after hysterectomy. Hysterectomy specimen revealed multiple small, tan to yellow nodules measuring 0.3-0.8 cm just below the endometrium. In the microscopic examination uniform neoplastic cells with varying cellularity were accompanied by necrotic zones and eosinophilic hyaline material. Immunohistochemically neoplastic cells were diffusely stained with CK 7, inhibin-alpha, p63, hPL, and CD146. There was no staining with beta-HCG, SMA, PLAP, or h-caldesmon. Ki-67 proliferative index was approximately 10% and cyclin E was stained in approximately 10% of the neoplastic cells. Although immunohistochemical studies are helpful in classifying gestational trophoblastic lesions, borderline values can cause diagnostic confusion between neoplastic and reactive lesions, particularly in inadequate endometrial biopsies.


Sujet(s)
Tumeurs trophoblastiques/anatomopathologie , Tumeurs de l'utérus/anatomopathologie , Adulte , Femelle , Humains , Hystérectomie , Résultats fortuits
6.
J Obstet Gynaecol ; 34(5): 429-34, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24734941

RÉSUMÉ

The objective of our study was to evaluate the accuracy of frozen section (FS) in borderline ovarian tumours (BOT) and to define the factors associated with misdiagnosis during FS evaluation. We performed a retrospective review of patients who underwent exploratory laparotomy for an adnexal mass, from January 2007 to July 2012, at a tertiary oncology centre in Turkey. Patients with a diagnosis of BOT either in FS or in permanent pathology were identified. Agreement between FS diagnosis and permanent histology was observed in 37/59 patients (62.7%), which gave a sensitivity and a positive predictive value of 71.2% and 84.1%, respectively. In patients with a diagnosis of BOT by frozen section only (n = 44), the diagnosis was consistent with permanent histopathology in 37/44 patients (84.1%). Frozen section interpreted a malignant tumour as BOT (under-diagnosis) in 6/44 (13.6%) of cases and interpreted a benign lesion as BOT (over-diagnosis) in 1/44 (2.3%) of cases. Slide review of discrepant cases revealed that major pathological causes of under-diagnosis were misinterpretation and sampling errors. Univariate analysis showed that presence of bilateral tumour and positive peritoneal cytology were associated with under-diagnosis. We concluded that, despite significant risk of under-diagnosis, FS analysis is an accurate method for intraoperative diagnosis of BOTs.


Sujet(s)
Erreurs de diagnostic , Coupes minces congelées , Tumeurs kystiques, mucineuses et séreuses/anatomopathologie , Tumeurs de l'ovaire/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Faux négatifs , Faux positifs , Femelle , Humains , Soins peropératoires , Adulte d'âge moyen , Tumeurs kystiques, mucineuses et séreuses/chirurgie , Tumeurs de l'ovaire/chirurgie , Valeur prédictive des tests , Études rétrospectives , Jeune adulte
8.
Clin Exp Obstet Gynecol ; 36(1): 31-4, 2009.
Article de Anglais | MEDLINE | ID: mdl-19400415

RÉSUMÉ

PURPOSE OF INVESTIGATION: To evaluate the accuracy of frozen section analysis in patients with atypical endometrial hyperplasia. METHODS: Women who underwent hysterectomy with frozen section analysis for atypical endometrial hyperplasia were identified. Frozen section evaluation aimed to give information about the presence of malignancy. Also, myometrial or cervical involvement was assessed in cases with malignancy to reveal the need for staging. Final pathological evaluation results were compared with intraoperative frozen section analyses. RESULTS: Twelve patients (34.3%) had endometrial cancer on final pathologic examination and eight required a staging procedure due to either myometrial invasion or cervical involvement; 75% of patients with endometrial cancer were successfully detected by frozen section analysis. Moreover, among women with cancer, frozen section examination revealed 75% of cases who required surgical staging. CONCLUSION: Frozen section analysis of hysterectomy specimens in patients with atypical endometrial hyperplasia is necessary to determine the presence of cancer and the need for surgical staging.


Sujet(s)
Hyperplasie endométriale/anatomopathologie , Tumeurs de l'endomètre/anatomopathologie , Coupes minces congelées , Hystérectomie , Adulte , Sujet âgé , Études cas-témoins , Femelle , Humains , Soins peropératoires , Adulte d'âge moyen , Stadification tumorale , Valeur prédictive des tests , Biopsie de noeud lymphatique sentinelle
9.
Int J Gynecol Cancer ; 18(6): 1294-9, 2008.
Article de Anglais | MEDLINE | ID: mdl-18284452

RÉSUMÉ

The objective of this study was to analyze the efficacy and morbidity of vaginal cuff brachytherapy alone in intermediate- to high-risk stage I endometrial cancer patients after complete surgical staging. Between October 1994 and November 2005, 128 patients with intermediate- to high-risk stage I endometrial adenocarcinoma were treated with high dose rate (HDR) brachytherapy alone after complete surgical staging. The intermediate- to high-risk group was defined as any stage I with grade 3 histology or stage IB grade 2 or any stage IC disease. The comprehensive surgery was in the form of total abdominal hysterectomy, bilateral salpingo-oophorectomy in addition to infracolic omentectomy, and routine pelvic and para-aortic lymphadenectomy. The median number of the lymph nodes dissected was 33. The median age at the time of diagnosis was 60 years. Forty patients were staged as IB (grade 2: 25 and grade 3: 15), and 88 patients were staged as IC (grade 1: 31, grade 2: 41, and grade 3: 16). A total dose of 27.5 Gy with HDR brachytherapy, prescribed at 0.5 cm, was delivered in five fractions in 5 consecutive days. Median follow-up was 48 months. Six (4.7%) patients developed either local recurrence (n = 2) or distant metastases (n = 4). Five-year overall survival and disease-free survival (DFS) rates are 96% and 93%, respectively. Only age was found to be significant prognostic factor for DFS. Patients younger than 60 years have significantly higher DFS (P = 0.006). None of the patients experienced grade 3/4 complications due to the vaginal HDR brachytherapy. Vaginal cuff brachytherapy alone is an adequate treatment modality in stage I endometrial adenocarcinoma patients with intermediate- to high-risk features after complete surgical staging with low complication rates.


Sujet(s)
Curiethérapie , Tumeurs de l'endomètre/radiothérapie , Tumeurs de l'endomètre/chirurgie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Curiethérapie/effets indésirables , Tumeurs de l'endomètre/anatomopathologie , Femelle , Humains , Adulte d'âge moyen , Invasion tumorale/anatomopathologie , Stadification tumorale , Récidive , Facteurs de risque , Taux de survie , Résultat thérapeutique
10.
Int J Gynecol Cancer ; 18(3): 556-9, 2008.
Article de Anglais | MEDLINE | ID: mdl-17692089

RÉSUMÉ

Congenital lymphangioma circumscriptum (LC) of the vulva is a rare disorder with unknown etiology. Treatment options include ablative approaches such as laser therapy, sclerotherapy, and surgery. Radiotherapy has been shown to be effective in the management of congenital lymphangioma especially in the thoracic and abdominal lesions. In this report, we describe a patient with persistent vulvar LC despite sclerosing therapy and several surgical excisions. She was treated with a course of external radiotherapy and showed a dramatic objective response with relief of all symptoms.


Sujet(s)
Lymphangiome/congénital , Lymphangiome/radiothérapie , Tumeurs de la vulve/congénital , Tumeurs de la vulve/radiothérapie , Adulte , Fractionnement de la dose d'irradiation , Femelle , Études de suivi , Humains , Lymphangiome/anatomopathologie , Imagerie par résonance magnétique , Stadification tumorale , Dosimétrie en radiothérapie , Appréciation des risques , Résultat thérapeutique , Tumeurs de la vulve/anatomopathologie
11.
Int J Gynecol Cancer ; 17(4): 843-50, 2007.
Article de Anglais | MEDLINE | ID: mdl-17343572

RÉSUMÉ

Epithelium cadherin (E-cad) is important for cell-to-cell adhesion of epithelial cells. Impairment of E-cad may have a role in the development and spreading of different malignancies and associated with poor differentiation, increased invasiveness, and poor prognostic factors in nongynecological carcinomas. However, prognostic significance of E-cad expression has not been investigated properly in cervical squamous cell carcinoma (SCC). The objective of this study was to investigate the association between reduced E-cad expression and clinicopathologic variables of cervical carcinoma. Specimens from 53 consecutive patients with stage IB-IIA SCC were evaluated immunohistochemically for E-cad expression, and the results were compared to grade, lymphvascular space invasion (LVSI), deep stromal involvement (DSI), parametrial involvement, lymph node metastasis, recurrences, and survival. Patients were divided into two groups arbitrarily: E-cad expression less than 10% (group 1) and E-cad expression more than 10% (group 2). There was no significant relationship between E-cad expression and DSI, LVSI, lymphatic metastasis. However, there was significant relationship between reduced E-cad expression and parametrial involvement (P= 0.024). Kaplan-Meier survival analysis revealed that reduced E-cad expression is significantly associated with reduced overall survival (OS) and disease-free survival (DFS). Furthermore, Cox regression analysis revealed that reduced E-cad expression is significantly associated with OS (P= 0.004, RR = 6.08, 95% CI: 1.75-21.1) and recurrences (P= 0.027, RR = 1.75, 95% CI: 1.06-2.88). We conclude that loss of E-cad expression is significantly associated with reduced OS and DFS in patients with SCC. Therefore, it might be used as an indicator of aggressive clinical behavior and tailoring aggressive adjuvant therapy in early-stage SCC. Further studies with larger number of patients are needed to evaluate the clinical significance of reduced E-cad expression in SCC.


Sujet(s)
Cadhérines/biosynthèse , Carcinome épidermoïde/métabolisme , Tumeurs du col de l'utérus/métabolisme , Adulte , Sujet âgé , Cadhérines/déficit , Cadhérines/métabolisme , Carcinome épidermoïde/anatomopathologie , Adhérence cellulaire/physiologie , Survie sans rechute , Cellules épithéliales/métabolisme , Cellules épithéliales/anatomopathologie , Femelle , Humains , Immunohistochimie/méthodes , Adulte d'âge moyen , Stadification tumorale , Tumeurs du col de l'utérus/anatomopathologie
12.
Int J Gynecol Cancer ; 17(1): 164-73, 2007.
Article de Anglais | MEDLINE | ID: mdl-17291249

RÉSUMÉ

The objective of the study was to compare cyclooxygenase-2 (COX-2) expression in cervical intraepithelial neoplasia III (CIN III) and squamous cell carcinoma (SCC) of the cervix, and its correlation with clinicopathologic factors of SCC with a review of the available literature. This study included 25 patients with CIN III and 67 patients with stage I-IIa SCC. All patients in the SCC group were treated with radical hysterectomy plus pelvic and para-aortic lymphadenectomy and postoperative chemoradiotherapy based on their histopathologic risk factors. Immunohistochemical analysis was performed on paraffin-embedded sections with COX-2 antibody. COX-2 expression in the SCC group was significantly higher than in the CIN III group (55.2% [37/67] vs 24% [6/25]; P= 0.008). Significantly higher expression of COX-2 was observed in patients with lymphovascular space invasion (LVSI) compared to patients without LVSI (61.9% [34/55] vs 33.3% [3/9]; P= 0.02). Additionally, patients with tumor sizes >4 cm had significantly higher COX-2 expression than patients with tumor sizes <4 cm (65.9% [27/41] vs 39% [10/26] P= 0.028). There was no significant relationship with respect to COX-2 expression and parametrial involvement, lymph node metastasis, recurrences, and survival. In multivariate analysis, LVSI was the only statistically significant determinant for COX-2 expression (P= 0.024; OR = 2.35; 95% CI = 1.1-4.9). Our results and a review of the literature both suggest that COX-2 expression may have a role in the development and progression of CIN III and it is related to some clinicopathologic variables of cervical carcinoma. Further studies are needed to clarify the role of COX-2 inhibitors in the management of CIN and SCC.


Sujet(s)
Carcinome épidermoïde/enzymologie , Cyclooxygenase 2/biosynthèse , Dysplasie du col utérin/enzymologie , Tumeurs du col de l'utérus/enzymologie , Adulte , Sujet âgé , Carcinome épidermoïde/anatomopathologie , Femelle , Humains , Immunohistochimie , Métastase lymphatique , Adulte d'âge moyen , Stadification tumorale , Tumeurs du col de l'utérus/anatomopathologie , Dysplasie du col utérin/anatomopathologie
13.
Int J Gynecol Cancer ; 16(2): 484-9, 2006.
Article de Anglais | MEDLINE | ID: mdl-16681715

RÉSUMÉ

The purpose of this study was to compare the effect of paclitaxel plus platinum-based chemotherapy in the treatment of extraovarian peritoneal serous papillary carcinoma (EPSPC) and ovarian serous papillary cancer (OSPC). Only the patients treated with initial surgery plus postoperative adjuvant chemotherapy and having FIGO stage IIIC disease with omental and/or peritoneal involvement were analyzed. Thirty-two patients with EPSPC and 43 with OSPC were included in this study. The median age, mean CA-125, and volume of ascitis were higher in patients with EPSPC. There was no significant difference between the two groups with respect to other prognosticators. The median overall survival (OS) durations were 30 months (95% CI 24.8-35.3) in patients with EPSPC and 28 months (95% CI 21.1-34.9) in those with OSPC (P= 0.35). The 3-year OS rates in the patients and controls were 28% and 31%, respectively (P= 0.84). In patients with EPSPC, only optimal cytoreduction was significantly related to progression-free survival and OS durations as a prognostic factor. In the EPSPC group, 65.5% of the patients (19/29) had lymphatic involvement, compared to 88.4% (38/43) in the OSPC group (P= 0.02). As an adjuvant therapy, the paclitaxel plus platinum-based combination regimen had similar effects on survival in the EPSPC and OSPC groups.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Carcinome papillaire/traitement médicamenteux , Cystadénocarcinome séreux/traitement médicamenteux , Tumeurs de l'ovaire/traitement médicamenteux , Tumeurs du péritoine/traitement médicamenteux , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Carboplatine/administration et posologie , Carcinome papillaire/mortalité , Carcinome papillaire/chirurgie , Cisplatine/administration et posologie , Cystadénocarcinome séreux/mortalité , Cystadénocarcinome séreux/chirurgie , Femelle , Humains , Métastase lymphatique/anatomopathologie , Adulte d'âge moyen , Tumeurs de l'ovaire/mortalité , Tumeurs de l'ovaire/chirurgie , Paclitaxel/administration et posologie , Tumeurs du péritoine/mortalité , Tumeurs du péritoine/chirurgie , Études rétrospectives , Taux de survie , Facteurs temps
14.
Eur J Gynaecol Oncol ; 27(2): 200, 2006.
Article de Anglais | MEDLINE | ID: mdl-16620073

RÉSUMÉ

Peritoneal mesothelioma is a rare cancer of the abdominal cavity which has low malignant potential. Peritoneal mesothelioma can mimic other types of gynecologic malignancies. Careful clinical and pathologic evaluation is essential for an accurate diagnosis and treatment.


Sujet(s)
Adénocarcinome/diagnostic , Tumeurs de l'endomètre/complications , Tumeurs de l'endomètre/diagnostic , Mésothéliome/diagnostic , Mésothéliome/étiologie , Tumeurs du péritoine/diagnostic , Sujet âgé de 80 ans ou plus , Ascites/étiologie , Diagnostic différentiel , Femelle , Humains , Immunohistochimie
15.
Int J Gynecol Cancer ; 15(6): 1142-7, 2005.
Article de Anglais | MEDLINE | ID: mdl-16343198

RÉSUMÉ

Primary ovarian fibrosarcomas are very rare tumors with great heterogeneity among reported cases. There are only a few reports of the subject in the literature, and along with the nature of the disease, diagnosis and treatment still remain to be established. In this report, we reviewed the cases published in the English literature within the past 30 years and tried to highlight certain aspects of the disease. A 52-year-old parous woman was admitted to our hospital with the complaints of abdominopelvic pain. Initial diagnostic work-up revealed a solid mass on the right ovary. After explorative laparotomy, the pathologic examination reported a primary ovarian fibrosarcoma. The patient has been free of disease for 1 year without any adjuvant therapy. Although ovarian fibrosarcomas are unusual causes of solid masses in postmenopausal women, it should be kept in mind when evaluating adnexal masses in this age group.


Sujet(s)
Fibrosarcome/anatomopathologie , Tumeurs de l'ovaire/anatomopathologie , Antinéoplasiques/usage thérapeutique , Femelle , Fibrosarcome/thérapie , Procédures de chirurgie gynécologique , Humains , Adulte d'âge moyen , Tumeurs de l'ovaire/thérapie , Résultat thérapeutique , Refus du traitement
16.
Eur J Gynaecol Oncol ; 25(6): 759-60, 2004.
Article de Anglais | MEDLINE | ID: mdl-15597862

RÉSUMÉ

A case of a 25-year-old primigravid woman at 31 weeks' gestation with the diagnosis of preeclampsia, malignant pelvic mass, fetal growth restriction and postpartum pulmonary thromboembolism is reported. Fertility preserving surgery for ovarian carcinoma following cesarean delivery was carried out. Final histopathology revealed Stage IC dysgerminoma. After eight months of initial surgery she became pregnant spontaneously. After two years of initial surgery she is still alive without any evidence of disease.


Sujet(s)
Dysgerminome/diagnostic , Tumeurs de l'ovaire/diagnostic , Pré-éclampsie/diagnostic , Complications tumorales de la grossesse/diagnostic , Diagnostic prénatal , Adulte , Césarienne , Diagnostic différentiel , Dysgerminome/complications , Dysgerminome/anatomopathologie , Dysgerminome/chirurgie , Femelle , Humains , Nouveau-né , Tumeurs de l'ovaire/complications , Tumeurs de l'ovaire/anatomopathologie , Tumeurs de l'ovaire/chirurgie , Pré-éclampsie/complications , Pré-éclampsie/anatomopathologie , Grossesse , Complications tumorales de la grossesse/anatomopathologie , Complications tumorales de la grossesse/chirurgie , Troisième trimestre de grossesse , Troubles du postpartum/complications , Troubles du postpartum/diagnostic , Troubles du postpartum/anatomopathologie , Embolie pulmonaire/complications , Embolie pulmonaire/diagnostic , Embolie pulmonaire/anatomopathologie
17.
Int J Gynecol Cancer ; 14(3): 558-63, 2004.
Article de Anglais | MEDLINE | ID: mdl-15228435

RÉSUMÉ

Placental site trophoblastic tumor is a rare neoplasm that arises from intermediate trophoblasts and shows diversity of biological behaviors, resulting in the absence of consistency in treatment modalities. A case of placental site trophoblastic tumor that extended to the cervix, with primary manifestation of amenorrhea and yellow foul-smelling vaginal discharge, is presented. Total abdominal hysterectomy was performed initially, and serial measurements of human chorionic gonadotropin levels were obtained. She was admitted with metastases to brain and lung 1.5 years after surgery. Combination chemotherapy (etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine) and radiotherapy were administered. There was no significant response to chemoradiotherapy. Despite changing chemotherapy regimen, she is still alive with progressive disease.


Sujet(s)
Tumeur trophoblastique du site d'implantation placentaire/diagnostic , Tumeurs de l'utérus/diagnostic , Adulte , Protocoles de polychimiothérapie antinéoplasique , Tumeurs du cerveau/diagnostic , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/secondaire , Tumeurs du cerveau/thérapie , Association thérapeutique , Diagnostic différentiel , Femelle , Humains , Tumeurs du poumon/diagnostic , Tumeurs du poumon/imagerie diagnostique , Tumeurs du poumon/secondaire , Tumeurs du poumon/thérapie , Imagerie par résonance magnétique , Métastase tumorale , Grossesse , Tomodensitométrie , Tumeur trophoblastique du site d'implantation placentaire/imagerie diagnostique , Tumeur trophoblastique du site d'implantation placentaire/secondaire , Tumeur trophoblastique du site d'implantation placentaire/thérapie , Tumeurs de l'utérus/imagerie diagnostique , Tumeurs de l'utérus/anatomopathologie , Tumeurs de l'utérus/thérapie
18.
Gynecol Obstet Invest ; 58(3): 151-4, 2004.
Article de Anglais | MEDLINE | ID: mdl-15249741

RÉSUMÉ

INTRODUCTION: Mammary glands located in the vulvar region have been named as ectopic breast tissue or anogenital mammary glands by different authors. Literature on pathologies of ectopic breast tissue located in the vulvar region is rare. Most of the reports are about the malignancies arising from this ectopic tissue. CASE REPORT: We report a case of fibrocystic disease of the mammary glands in the vulva in a 25-year-old pregnant woman. Her disease was exaggerated during pregnancy. CONCLUSION: Ectopic breast tissue in the vulva is a rare entity and fibrocystic disease of this tissue has rarely been reported in the English literature.


Sujet(s)
Région mammaire , Choristome/anatomopathologie , Maladie fibrokystique du sein/anatomopathologie , Complications de la grossesse/anatomopathologie , Maladies de la vulve/anatomopathologie , Adulte , Femelle , Humains , Glandes mammaires humaines , Grossesse , Vulve/anatomopathologie
19.
Eur J Gynaecol Oncol ; 25(3): 381-3, 2004.
Article de Anglais | MEDLINE | ID: mdl-15171325

RÉSUMÉ

Primary extragenital leiomyosarcoma is rarely found in pelvic localization. A 33-year-old multiparous woman who had recurrent low-grade leiomyosarcoma presented with the complaints of dyspareunia, pelvic pain and gait disturbance. Her past medical history revealed she had been subjected to maximal excision of a paravaginal mass by using vaginal and suprapubic transverse incision three years before. The pathology report showed that she had leiomyoma. Three years after the initial surgery, a paravaginal fixed mass was observed at the initial tumor bed and removed by the perineal approach. The histological examination of the specimen revealed a low grade leiomyosarcoma. She was discharged from hospital without any complications.


Sujet(s)
Léiomyosarcome/diagnostic , Récidive tumorale locale/diagnostic , Tumeurs du péritoine/diagnostic , Tumeurs du vagin/diagnostic , Adulte , Diagnostic différentiel , Femelle , Humains , Léiomyosarcome/imagerie diagnostique , Léiomyosarcome/anatomopathologie , Léiomyosarcome/chirurgie , Récidive tumorale locale/imagerie diagnostique , Récidive tumorale locale/secondaire , Récidive tumorale locale/chirurgie , Tumeurs du péritoine/imagerie diagnostique , Tumeurs du péritoine/secondaire , Tumeurs du péritoine/chirurgie , Tomodensitométrie , Tumeurs du vagin/imagerie diagnostique , Tumeurs du vagin/secondaire , Tumeurs du vagin/chirurgie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE